Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00149734 · ClinicalTrials.gov registry record · Phase 3
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00149734 is a Phase 3 study of Schizophrenia that has completed, run by University of Colorado, Denver. The registered enrollment target is 8 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00149734, a Phase 3 study of Schizophrenia, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
Conditions Studied
Interventions
- DRUG Ondansetron followed by placebo
- DRUG Placebo followed by Ondansetron
Study Locations (1)
Colorado
- Denver VAMC - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00149734
The ClinicalTrials.gov registry entry for NCT00149734 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (96% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Ondansetron followed by placebo is the first listed.
NCT00149734 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT00149734 about?
NCT00149734 is a clinical study titled "Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia". This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
What is the current status of trial NCT00149734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2005-01. Estimated completion is 2010-05.
What conditions does trial NCT00149734 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00149734?
The interventions under investigation include: Ondansetron followed by placebo (DRUG), Placebo followed by Ondansetron (DRUG).
Who is sponsoring clinical trial NCT00149734?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00149734 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.